HemoCath pioneers advancements at the crossroads of Medtech and Digital Health, aiming to enhance care for patients in critical care and individuals with heart failure.​The versatile and scalable HemoCath™ AI Platform enables proactive AI-data-driven management of patients with acute heart failure (HF) from diagnosis to treatment and monitoring for all hospital heart procedures. The user-friendly integrated Platform includes the HemoCath™ PA catheter securely connected to the Luc™ AI Cloud to continuously measure and monitor PAP & CVP, the leading indicators of heart congestion, allowing early targeted therapy. The vital health information remains easily available to the managing clinician, supporting optimal dosing of guideline-directed medical therapy (GDMT) across the entire spectrum of HF. Several clinical trials provide clinical evidence of a significant improvement in cardiac care and reduction in hospital stay ​with PAP-guided HF management.

Crosslake Capital is a search fund focused on acquiring and growing companies facing succession challenges.